New CDC guidance: Only high-risk groups should get monkeypox antiviral
9/18/22
< < Go Back
from The Washington Post,
9/16/22:
The Centers for Disease Control and Prevention issued new guidance Thursday recommending that TPoxx, the only drug available to treat monkeypox, be limited to people at high risk for severe disease even as the outbreak that has infected more than 22,000 Americans shows signs of plateauing.
Recently released data from the Food and Drug Administration suggest that broad use of TPoxx “could promote resistance and render the antivirals ineffective for some patients,” the CDC said in a statement Thursday.
More From The Washington Post (subscription required):
Rss Feed